findmyKOL
Clinical trialNCT04936997CompletedEarly phase 1Interventional

Immune Response to the COVID-19 Vaccine

SponsorUniversity of ArizonaEnrollment20CancerCovid19MalignancyVaccine Response Impaired
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Arizona

    Tucson, Arizona, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

SARS-COV2 Pfizer Vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Jun 2021
Primary completion
25 Aug 2021
Completion
8 May 2022
Last update posted
20 May 2022
Registered enrollment
20
Registry id
NCT04936997
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.